Skip to main content
. 2022 Nov 14;12(11):e060983. doi: 10.1136/bmjopen-2022-060983

Figure 3.

Figure 3

Tornado diagram for univariable sensitivity analyses. The grey dotted line represents the incremental cost-effectiveness ratio of US$850.6842 per quality-adjusted life year from the base-case results. ECF/ECX, epirubicin, cisplatin plus fluorouracil or capecitabine; FLOT, fluorouracil, leucovorin, oxaliplatin plus docetaxel; OS, overall survival; PFS, progression-free survival.